Carbonyl iron reduces anemia and improves effectiveness of treatment in under six-year-old children

Iria L. G. Farias1
Elisangela Colpo2
Salimara R. Botton3
Rosirene B. Silveira3
Adriane Fleig4
Carlos Andre A. Schimitz5
José Edson P. Silva6

Introduction

Iron deficiency has been considered an important risk factor for ill health, and it is estimated which iron deficiency affects 2 billion people worldwide.1 Depletion of iron stores leads to iron deficiency anemia and other serious impairments in the cognitive and intellectual developments.2 Treatment of iron deficiency anemia in children usually consists in the use of ferrous sulfate solution, but this treatment does not always have the desired effectiveness. The aim of this study was to evaluate the effectiveness of chewable carbonyl iron tablets as an alternative for the treatment of iron deficiency anemia in under six-year-old children. Seventy-three children from Brazilian Family Health Units in Santa Maria, Brazil, were included in this study. One group received chewable carbonyl iron (CI) tablets and a control group received a solution of ferrous sulfate (FS) for 90 days, both at a dose of 5 mg/Kg/day. Blood was drawn from study participants at 0, 30 and 90 days of treatment to evaluate the whole blood test, ferritin concentration, serum iron, and total iron binding capacity. We also evaluated the acceptance and adherence to treatment, and the occurrence of side effects during treatment. Hemoglobin increased 1.3 g/dL in the CI Group and 1.2 g/dL in the FS Group during the first 30 days of treatment. After 90 days of treatment, the CI Group had significantly better results for hematocrit, MCV, MCH, iron binding capacity and ferritin concentration compared to the FS Group. The ferritin concentration was significantly higher in the CI Group at the end of the treatment (9.51 ng/mL to 26.16 ng/mL). Additionally, the treatment was better accepted with fewer adverse effects by this group. Chewable carbonyl iron tablets should be considered an important therapeutic option in the treatment of iron deficiency anemia of under six-year-old children. Rev. Bras. Hematol. Hemoter. 2009;31(3):125-131.

Key words: Iron deficiency anemia; iron carbonyl; ferrous sulfate; children.
impregnation in the tooth), prolonged daily administration of drops, metallic taste, as well as to cultural aspects. Thus, some aspects should be considered to choose the adequate pharmaceutical preparation, including iron ion content, tolerance, absorption, effectiveness, and cost.

Carbonyl iron powder is obtained through decomposition of Fe pentacarbonyl at high temperatures, and result an extremely pure elemental Fe (Fe₀) in the form of non-toxic micro-spheres of 4-7µm, with bioavailability 58%-70% in relation to ferrous sulfate. Carbonyl iron powder was chosen as raw material especially because it does not give a metallic taste to pharmaceutical preparation, and it presents fewer gastrointestinal adverse effects than ferrous sulfate.

Therefore, it is necessary to investigate new alternatives for iron deficiency anemia treatment, especially for children under six years old, in order to improve the adherence to treatment. The aim of this study was to evaluate the effectiveness of carbonyl iron chewable tablets as an alternative for iron deficiency anemia treatment in children under six years old. We also investigated the acceptance, adherence, and the occurrence of gastrointestinal adverse effects during the treatment.

Patients and Method

Study population and design

This is an open, randomized and controlled clinical trial, which utilized ferrous sulfate as iron standard. The studied group was selected randomly, and children included in this group received carbonyl iron (CI), whereas children included in the control group received a solution of ferrous sulfate (FS), both at a dose of 5mg/Kg/day, during a period of 90 days. Medication was given to the children one hour before the lunch in both groups. The Ethics Committee of the Universidade Federal de Santa Maria approved this research protocol (number 0052.0.246.000-05). All mothers or legal guardian of the children signed an informed consent form. The study protocol was performed in accordance to the Declaration of Helsinki and the specific guidelines of the National Health Council (Brazil). Practices of the National Agency of Sanitary Surveillance (Anvisa, Brazil). Each tablet contained 25 mg of elemental iron. Ferrous sulfate used in this study was obtained from the Ministry of Health from Brazil.

Blood analysis

Blood samples were collected 0, 30 and 90 days after the beginning of treatment. The hemograms were automatically carried out in the Coulter STKS® analyzer (Coulter Electronics, USA). Serum ferritin was measured automatically by immunochromiluminescence assay in the IMMULITE® analyzer (DPC, Los Angeles, USA). Serum iron and total iron binding capacity were measured by use of HITACHI 917® analyzer (Hitachi, Tokyo, Japan). Transferrin saturation was calculated by dividing the concentration of serum iron by the total iron binding capacity multiplied by 100.

Interview

A questionnaire containing objective questions was used in an interview with a family member or legal guardian of the child at 30 days after the beginning of treatment. The medication acceptance, treatment adherence, and the occurrence of adverse effects were verified by use of this questionnaire.

Statistics

Data were analyzed with EpInfo program, version 3.3.2, of the CDC/USA. The data were evaluated by analysis of variance (ANOVA) and expressed as mean ±SEM. Difference between the groups (CI and FS) was evaluated by Student t test, where the difference between the baseline x 30 days of treatment and baseline x 90 days of treatment in the same group was evaluated by t test. When the variances were not homogenous, ANOVA was not appropriate (Bartlett’s P-value<0.05), so Wilcoxon two-sample test evaluated the data. P<0.05 was considered statistically significant.

Results

The average age of the studied children was 20 months (minimum of 6 months and maximum of 54 months), where 50% were ≤18 months. Blood samples of 142 children were collected in order to select the group, and 86 (60.56%) of these had anemia considering the criteria defined in this study. Three children that presented α-thalassemia, one that presented non-iron deficiency anemia, and three that presented accentuated eosinophilia were excluded of this study. In relation to 73 children that began the study, 62 returned at day 30, and 56 completed the 90 days of supplementation.

The studied group (CI, n=38) and control group (FS, n=35) were selected randomly, and the initial Hb was 9.37 g/dL for CI group and 8.99 g/dL for FS group, and no significant differences between the groups were observed. Serum iron,
TIBC, transferrin saturation, and ferritin values also did not vary significantly between the groups. Baseline values observed in both groups were reported in Table 1.

CI group presented a hemoglobin increase of 1.3 g/dL (minimum value of 0.4 and a maximum of 4.1 g/dL) after 30 days of treatment. There was a hemoglobin increase of 1.2 g/dL (minimum value of 0.9 and a maximum of 4.9 g/dL) in FS group. No children presented Hb decrease in CI group. However, there were three children that presented an Hb decrease in FS group. There was a 58.6% favorable response in CI group, and 48.4% favorable response in FS group, when the increase of Hb > 1 g/dL after 30 days of treatment was considered as a favorable response.

At 30 days, the percentage of children with a high erythrocyte count (RBC>5x10⁶/µL) for CI group ranged to 24-44%, and this percentage ranged to 25%-33% for FS group. CI group presented a significant difference in MCH in relation to RBC (p<0.001). Fourteen of the 32 children that presented a high erythrocyte count (>5.10⁶/µL) presented lower MCH (19.56 ± 2.7 fl), and 18 children with low erythrocyte count (RBC< 5x10⁶/µL) presented higher MCH (23.31 ± 2.6 fl). No MCH differences were observed in FS group.

The evaluation of pharmaceutical form acceptance indicated favorable results for CI group, and 31 individuals reported a very good acceptance for the following items: flavor, aroma, hardness, size, and pharmaceutical form. In this group, just a child refused the medication (3.12%), and this occurred 20 days after treatment. A total of 67.3% of the children from FS group refused to take the medication at some time because they had not liked of drops taste. Probably this finding collaborates for reduction of effectiveness after 90 days. Adverse effects were absent in children of CI group, except for feces darkening. In FS group, 20% of children presented diarrhea, 36% experienced vomiting and/or spat out the medication, 6% experienced vomiting and diarrhea, and 38% did not present any adverse effect.

Oral ferrous sulfate supplementation in the form of drops was the medical prescription for most of children. Thus, only children who had not been taking ferrous sulfate for at least 30 days participated of this study. Therefore, it was possible to compare both medications. Ease of administration, acceptance by the children in relation to the flavor, a lack of adverse effects, and effectiveness of the treatment were some positive aspects confirmed by children mothers or guardians for CI group.

There were not significant differences between groups for Hb, RBC, and RDW after 90 days. Hemoglobin increased from 9.37 g/dL to 11.36 g/dL in CI group, and from 8.99 g/dL to 10.68 g/dL in FS group. There were significant differences between the groups for Ht, MCH and MCV. We also observed significant differences in ferritin and TIBC levels. In CI group, all variables presented significant differences after 90 days of treatment in comparison to initial values, except for RBC. No significant differences were observed in FS group for RBC, ferritin, and RDW values. There was observed a ferritin increase in CI group at the end of treatment (9.51 ng/mL to 26.16 ng/mL). There was also observed a discrete ferritin increase in FS group (10.75 ng/mL to 13.41 ng/mL). These data was shown in Table 2 and Figure 1. A total of 3.7% of children from CI group (1/27) continued presenting Hb<10g/dL after the end of treatment, whereas this percentage was 31% (9/29) for FS group. A total of 33% of children in CI group (9/27), and 59 % from FS group (17/29) presented Hb<11g/dL. Table 3 summarizes some studies that evaluated iron deficiency anemia treatments, and also compare these results with our findings.

**Discussion**

This is the first clinical trial that evaluated the effectiveness of carbonyl iron for treatment of iron deficiency anemia in children under six years old. There was not a
significant difference between the groups in relation to effectiveness if only an increase of Hb after 30 days of treatment was considered a measure of effectiveness. Similar data has been found in other clinical trials by use of carbonyl iron and ferrous sulfate in adults.6 We compared the Hb increase observed in the carbonyl iron group with other studies3,4,11,12,13 that utilized other iron sources or other therapeutic strategies, and no important variations were observed, except for study conducted by Pineda et al.,12 which evaluated a ferrous bys-glycinate chelate treatment, and they observed a significant Hb increase. Another study13 that evaluated the use of prophylactic doses of ferrous sulfate demonstrated a smaller Hb increase, which reveals the need for greater doses in the iron deficiency anemia treatment. However, it should be considered that initial Hb in this study was close to the cut-off point for anemia, defined as 11g/dL.13 This similarity between our results and those of other studies demonstrates the therapeutic potential of carbonyl iron for the treatment of iron deficiency anemia.

In relation to adverse effects, our data for FS group in relation to diarrhea was similar to other studies,3 which reported that 18% of children experienced diarrhea during the treatment with FS 5 mg/Kg/day. In this study, there was no variation between daily single doses and the same dose fractioned into 3 daily doses. Other study using a prophylactic amount of 12 mg/day of iron reported that 12.4% of children experienced diarrhea, which differs from our data possibly due to dose differences.13 In relation to vomiting in FS group, mothers reported that it occurred immediately after swallowing. The vomiting could be related to medication flavor, which is difficult to mask at elevated doses. Therefore, the vomiting was grouped together with the refusal to medication swallow, which was the most common adverse effect reported by mothers. Zlotkin et al.2 reported that 74% of children taking FS cried and/or refused to take the medicine. These data reflect an important aspect that is very favorable for CI group: the children’s acceptance of tablet.

These data may corroborate with results observed after 90 days of treatment, where there are observed significant variations between the groups. Although there was not a significant difference in Hb levels in both groups, there was a significant difference between ferritin and TIBC levels. These data corroborated with a previous study,14 which demonstrated the necessity to determine the quantity of corporal iron. The ratio of serum transferrin receptor to serum ferritin was used to better evaluate the impact of iron supplementation, because the determination of Hb was inappropriate to determine iron status. A patient reevaluation after an intervention by use of ferrous sulfate demonstrated no significant difference in Hb levels between groups, whereas a difference was easily identified after corporal iron estimation.14

The determination of hemoglobin content in the reticulocyte reflects the balance between iron and erythropoiesis, although it is limited by the lower availability of iron to synthesize hemoglobin.15 Microcytosis and hypochromia were more severe in patients with high RBC values, regardless of iron status. Iron available per cell in patients with a high erythrocyte count is less than iron available in patients with a low RBC, and a high erythrocyte count may be accompanied by greater microcytosis and hypochromia.16 This finding was observed in our study. We also observed an increase in the number of children with high erythrocyte count, as a response to iron supplementation in CI group, and this increase was higher than the increase observed in FS group. As a consequence, there was a small increase in the MCH level at 30 days. The variables investigated in CI group after 90 days of treatment were very near to cut-off point for anemia, but the Hb, Ht, serum iron, TS, TIBC, and ferritin exceeded these limits. In FS group, the difference to cut-off point was greater. The mean value of

<table>
<thead>
<tr>
<th>Measurements</th>
<th>Units</th>
<th>FS Group</th>
<th>CI Group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Baseline (n=35)</td>
<td>90 days (n=29)</td>
</tr>
<tr>
<td>iron</td>
<td>µg/dL</td>
<td>24.00±2.14^b</td>
<td>43.88±5.23^A,a</td>
</tr>
<tr>
<td>TIBC</td>
<td>µg/dL</td>
<td>415.17±17.41^b</td>
<td>321.38±16.49^B,a</td>
</tr>
<tr>
<td>TS</td>
<td>%</td>
<td>6.01±0.51^b</td>
<td>16.70±2.28^A,a</td>
</tr>
<tr>
<td>ferritin</td>
<td>ng/dL</td>
<td>10.75±2.21^a</td>
<td>13.41±1.74^B,a</td>
</tr>
</tbody>
</table>

Data are reported as mean ± SEM. Values in the same row that do not share the same upper case superscript letters are significantly different between the FS and CI groups at 90 days (*P<0.002 and **P<0.001, ANOVA). Values in the same row that do not share the same lower case superscript letter are significantly different in the groups, baseline (without treatment) and after 90 days of treatment (P<0.05, ANOVA and Wilcoxon two-sample Test). Iron: serum iron; TIBC: total iron binding capacity; TS: transferrin saturation; ferritin: serum ferritin.
Figure 1. Erythrogram evolution after 30 and 90 days of treatment. Children received carbonyl iron (CI) or ferrous sulfate (FS), both at dose of 5mg elemental iron/Kg/day. Data are reported as mean ± SEM.

* $P < 0.05$ between groups at 90 days of treatment (Wilcoxon Two-Sample Test); * $P < 0.05$ between groups at 90 days of treatment (ANOVA); $\dagger P < 0.001$ baseline versus after 90 days of treatment into same group (Wilcoxon Two-Sample Test); $\ddagger P < 0.05$ baseline versus after 90 days of treatment into same group (ANOVA).

---

**RBC**

- **CI**
- **FS**

**Hemoglobin**

- **CI**
- **FS**

**Hematocrit**

- **CI**
- **FS**

**MCH**

- **CI**
- **FS**

**MCV**

- **CI**
- **FS**

---

Figure 1. Erythrogram evolution after 30 and 90 days of treatment. Children received carbonyl iron (CI) or ferrous sulfate (FS), both at dose of 5mg elemental iron/Kg/day. Data are reported as mean ± SEM.

* $P < 0.05$ between groups at 90 days of treatment (Wilcoxon Two-Sample Test); * $P < 0.05$ between groups at 90 days of treatment (ANOVA); $\dagger P < 0.001$ baseline versus after 90 days of treatment into same group (Wilcoxon Two-Sample Test); $\ddagger P < 0.05$ baseline versus after 90 days of treatment into same group (ANOVA).
ferritin in CI group (26.16 ng/mL) was two-fold compared to FS group (13.41 ng/mL), and this difference may reflect better results of hematological values (MCV, MCH) observed in this group.

In relation to treatment effectiveness after 90 days, the number of children from control group that continued to present hemoglobin level lower than 11g/dL was two-fold in comparison to the group that received carbonyl iron. Our results with carbonyl iron demonstrated the same effectiveness at 30 days of standard ferrous sulfate treatment, and better results at 90 days of treatment, together with excellent acceptance. These data added to the safety (low toxicity) allow concluding that carbonyl iron constitutes an important option for therapeutic treatment of iron deficiency anemia in children under six years old; moreover its use could be considered as an alternative for public health prevention programs.

**Resumo**

O tratamento da anemia ferropriva de crianças consiste, em sua maioria, no uso de solução de sulfato ferroso e este tratamento nem sempre apresenta a efetividade desejada. O objetivo deste estudo foi avaliar a efetividade do ferro carbônico, na forma de comprimidos mastigáveis, como uma alternativa de tratamento para anemia ferropriva de crianças menores de seis anos de idade. Foram incluídas no estudo 73 crianças atendidas em PSFs de Santa Maria, RS. Um grupo recebeu comprimidos mastigáveis de ferro carbônico (CI) e o grupo controle recebeu solução de sulfato ferroso (FS), ambos a dose de 5mg/kg/dia por 90 dias. Amostras de sangue foram coletadas nos dias zero, 30 e 90 do tratamento para avaliação de hemograma, ferritina, ferro sérico e capacidade total de ligação do ferro. Também foi avaliada a aceitação e aderência ao tratamento e relato de efeitos colaterais durante o tratamento. A hemoglobina teve um incremento de 1,3g/dL no grupo CI e 1,2g/dL no grupo FS aos 30 dias de tratamento. Após 90 dias de tratamento, o grupo CI apresentou resultados significativamente melhores para hematocrito, VCM, HCM, CTLF e ferritina. A ferritina do grupo CI teve um importante aumento ao final do tratamento (9,51ng/mL para 26,16ng/mL). O grupo CI apresentou melhor aceitação do tratamento e menos efeitos colaterais. Comprimidos mastigáveis de ferro carbônico poderiam ser considerados uma importante opção terapêutica para tratamento da anemia ferropriva de crianças menores de seis anos de idade. Rev. Bras. Hematol. Hemoter. 2009; 31(3):125-131.

**Palavras-chave:** Anemia ferropriva; ferro carbônico; sulfato ferroso; crianças.

**References**


---

### Table 3. Increase of hemoglobin (Hb) as a measure of effectiveness for the treatment of iron deficiency anemia in children. Comparison of the present study with other studies referenced.

<table>
<thead>
<tr>
<th>Clinical Trial</th>
<th>Patients</th>
<th>Drug/dose</th>
<th>Initial Hb (g/dL)</th>
<th>Hb day 30 (g/dL)</th>
<th>Hb 30 days (g/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pineda et al. 14</td>
<td>6-36 month old children</td>
<td>FS 5mg/Kg/day; Fe Bis-glycinate chelate 5mg/Kg/day</td>
<td>8.7</td>
<td>10.5</td>
<td>1.80</td>
</tr>
<tr>
<td>Torres et al. 15</td>
<td>4-36 month old children</td>
<td>FS 12 mg/day</td>
<td>10.6</td>
<td>11.28</td>
<td>0.68</td>
</tr>
<tr>
<td>Zlotkin et al. 5</td>
<td>6-24 month old children</td>
<td>FS 5mg/Kg/day; 1x/day FS 5mg/Kg/day; 3x/day</td>
<td>8.8</td>
<td>10.2</td>
<td>1.4</td>
</tr>
<tr>
<td>Schultink et al. 6</td>
<td>2-5 year old children</td>
<td>FS 30mg Fe, 2xweek FS 30 mg daily</td>
<td>10.8</td>
<td>11.4</td>
<td>0.60</td>
</tr>
<tr>
<td>Zlotkin et al. 13</td>
<td>6-18 month old children</td>
<td>Ferrous fumarate 5mg/Kg/day FS 5mg/Kg/day</td>
<td>8.7</td>
<td>10.2</td>
<td>1.5</td>
</tr>
<tr>
<td>Present study</td>
<td>5-72 month old children</td>
<td>FS 5mg/Kg/day; CI 5mg/Kg/day</td>
<td>9.99</td>
<td>10.18</td>
<td>1.19</td>
</tr>
</tbody>
</table>


